OBJECTIVE: To examine the prevalence and distribution among racial/ethnic groups of polyomavirus SV40 antibodies in women in Houston, Texas. METHODS: Women in three different cohorts reflecting the evolving demographics of Houston were evaluated for frequency of SV40 antibodies using a plaque-reduction neutralization assay. RESULTS: Women in cohort A (enrolled 1972-1973) were 68% (145/212) African-American and 32% Caucasian; the overall frequency of SV40 neutralizing antibodies was 7%. Women in cohort B (enrolled 1975-1977) were Caucasian with an overall frequency of SV40 neutralizing antibodies of 18% (37/211). Women in cohort C (enrolled 1993-1995) were 50% (199/400) African-American, 25% Caucasian, and 25% Hispanic; the overall frequency of SV40 neutralizing antibodies was 10%. Logistic regression analysis for cohort A showed no difference in SV40 neutralizing antibodies with respect to race/ethnicity, pregnancy status, number of previous pregnancies, or history of sexually transmitted diseases. For cohort C, race/ethnicity was identified as a significant factor associated with SV40 neutralizing antibodies, with Hispanics having a seroprevalence of 23% compared to 5-6% in the other two groups (p = 0.01). CONCLUSIONS: A significantly higher SV40 seroprevalence was found among Hispanics than other racial/ethnic groups in the city of Houston. Findings are compatible with a model that certain population groups potentially exposed to SV40-contaminated oral poliovaccines have maintained cycles of SV40 infections.
OBJECTIVE: To examine the prevalence and distribution among racial/ethnic groups of polyomavirusSV40 antibodies in women in Houston, Texas. METHODS:Women in three different cohorts reflecting the evolving demographics of Houston were evaluated for frequency of SV40 antibodies using a plaque-reduction neutralization assay. RESULTS:Women in cohort A (enrolled 1972-1973) were 68% (145/212) African-American and 32% Caucasian; the overall frequency of SV40 neutralizing antibodies was 7%. Women in cohort B (enrolled 1975-1977) were Caucasian with an overall frequency of SV40 neutralizing antibodies of 18% (37/211). Women in cohort C (enrolled 1993-1995) were 50% (199/400) African-American, 25% Caucasian, and 25% Hispanic; the overall frequency of SV40 neutralizing antibodies was 10%. Logistic regression analysis for cohort A showed no difference in SV40 neutralizing antibodies with respect to race/ethnicity, pregnancy status, number of previous pregnancies, or history of sexually transmitted diseases. For cohort C, race/ethnicity was identified as a significant factor associated with SV40 neutralizing antibodies, with Hispanics having a seroprevalence of 23% compared to 5-6% in the other two groups (p = 0.01). CONCLUSIONS: A significantly higher SV40 seroprevalence was found among Hispanics than other racial/ethnic groups in the city of Houston. Findings are compatible with a model that certain population groups potentially exposed to SV40-contaminated oral poliovaccines have maintained cycles of SV40 infections.
Authors: Sonia Toracchio; Claudia A Kozinetz; Deanna E Killen; Andrea M Sheehan; Eugenio I Banez; Michael M Ittmann; Vojtech Sroller; Janet S Butel Journal: J Clin Virol Date: 2009-07-23 Impact factor: 3.168
Authors: John A Vanchiere; Suhaib Abudayyeh; Christina M Copeland; Lee B Lu; David Y Graham; Janet S Butel Journal: J Clin Microbiol Date: 2009-06-03 Impact factor: 5.948
Authors: Rui-Mei Li; Mary H Branton; Somsak Tanawattanacharoen; Ronald A Falk; J Charles Jennette; Jeffrey B Kopp Journal: J Am Soc Nephrol Date: 2002-09 Impact factor: 10.121
Authors: H Yamamoto; T Nakayama; H Murakami; T Hosaka; T Nakamata; T Tsuboyama; M Oka; T Nakamura; J Toguchida Journal: Br J Cancer Date: 2000-05 Impact factor: 7.640
Authors: Elisa Mazzoni; Mariantonietta Di Stefano; Josè R Fiore; Federica Destro; Marco Manfrini; John Charles Rotondo; Maria V Casali; Fortunato Vesce; Pantaleo Greco; Gennaro Scutiero; Fernanda Martini; Mauro G Tognon Journal: Front Immunol Date: 2017-04-10 Impact factor: 7.561